Baillie Gifford & Co. recently announced the acquisition of new stake in Exscientia plc (NASDAQ:EXAI). The institutional investor has increased its shareholding in the Healthcare company by 0.14% to 4.88 million shares with purchase of 6895.0 shares. This fresh investment now brings its stake to 4.04% valued currently at $26.0 million. In addition, Platinum Investment Management Lt raised its holdings by 0.71 million to 2.81 million shares. And Marshall Wace LLP has lifted its position by 1.58% or 25554.0 shares – to 1.64 million shares.
With over 0.28 million Exscientia plc (EXAI) shares trading Friday and a closing price of $7.05 on the day, the dollar volume was approximately $1.97 million. The shares have shown a negative half year performance of -29.57% and its price on 01/13/23 gained nearly 8.63%. Currently, there are 122.67M common shares owned by the public and among those 102.57M shares have been available to trade.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
The top 3 mutual fund holders in Exscientia plc are BlackRock Global Allocation Fund, BlackRock Global Funds – Global A, and Pictet – Biotech. BlackRock Global Allocation Fund owns 1.93 million shares of the company’s stock, all valued at over $10.27 million. The company bought an additional 1.93 million shares recently to bring their total holdings to about 1.59% of the shares outstanding. Pictet – Biotech bought 0.84 million shares to bring its total holdings to over 0.84 million shares at a value of $4.49 million. Pictet – Biotech now owns shares totaling to 0.70% of the shares outstanding.
Shares of Exscientia plc (NASDAQ: EXAI) opened at $6.45, down -$0.04 from a prior closing price of $6.49. However, the script later moved the day high at 7.05, up 8.63%. The company’s stock has a 5-day price change of 16.14% and -3.56% over the past three months. EXAI shares are trading 32.27% year to date (YTD), with the 12-month market performance down to -62.10% lower. It has a 12-month low price of $4.09 and touched a high of $24.74 over the same period. EXAI has an average intraday trading volume of 204.20K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 37.40%, 22.37%, and -24.77% respectively.
Institutional ownership of Exscientia plc (NASDAQ: EXAI) shares accounts for 23.00% of the company’s 122.67M shares outstanding. Mutual fund holders own 7.05%, while other institutional holders and individual stakeholders account for 9.75% and — respectively.
It has a market capitalization of $797.50M. The earnings-per-share (ttm) stands at -$1.00. Price movements for the stock have been influenced by the stock’s volatility, which stands at 7.13% over the week and 8.81% over the month.
Analysts forecast that Exscientia plc (EXAI) will achieve an EPS of -$0.31 for the current quarter, -$0.27 for the next quarter and -$1.78 for 2023. The lowest estimate earnings-per-share for the quarter is -$0.41 while analysts give the company a high EPS estimate of -$0.22. Comparatively, EPS for the current quarter was -$0.08 a year ago. Earnings per share for the fiscal year are expected to decrease by -116.20%, and -52.30% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 4 brokerage firm advisors rate Exscientia plc (EXAI) as a “Moderate Buy” at a consensus score of 2.00. Specifically, 2 Wall Street analysts polled rate the stock as a buy, while 1 of the 4 advise that investors “hold,” and 0 rated it as a “Sell.”
